Loading…
p53 and disease progression in patients with non-small cell lung cancer
Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight c...
Saved in:
Published in: | Surgical oncology 1995-06, Vol.4 (3), p.157-161 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3 |
container_end_page | 161 |
container_issue | 3 |
container_start_page | 157 |
container_title | Surgical oncology |
container_volume | 4 |
creator | Sauter, E.R. Gwin, J.L. Mandel, J. Keller, S.M. |
description | Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread (
P = 0.06), and p53 expression correlated significantly (
P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC. |
doi_str_mv | 10.1016/S0960-7404(10)80020-9 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77704943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960740410800209</els_id><sourcerecordid>77704943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3</originalsourceid><addsrcrecordid>eNqFkE9PAyEQxYnR1Fr9CE04GT2sDuwusCdjGq0mTTyoZ0JhWjEtW2Gr8dtL_6RXL0DmvZk3_AgZMrhhwMTtKzQCCllBdcXgWgFwKJoj0mdKNkVZcjgm_YPllJyl9AkAQnLWIz1ZK86U6pPxqi6pCY46n9AkpKvYziOm5NtAfaAr03kMXaI_vvugoQ1FWprFglrMx2Id5tSaYDGek5OZWSS82N8D8v748DZ6KiYv4-fR_aSwpYCuMA4rzk3jKuYUn-LMMYsSp1kUdcWEYNOZaxpW54eTAhnwSkklUSiuSmnLAbnczc17fq0xdXrp02YZE7BdJy2lhKqpymysd0Yb25QizvQq-qWJv5qB3gDUW4B6Q2dT2gLUTe4b7gPW0yW6Q9eeWNbvdjrmX357jDrZTMii8xFtp13r_0n4A3S0fs4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77704943</pqid></control><display><type>article</type><title>p53 and disease progression in patients with non-small cell lung cancer</title><source>Elsevier</source><creator>Sauter, E.R. ; Gwin, J.L. ; Mandel, J. ; Keller, S.M.</creator><creatorcontrib>Sauter, E.R. ; Gwin, J.L. ; Mandel, J. ; Keller, S.M.</creatorcontrib><description>Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread (
P = 0.06), and p53 expression correlated significantly (
P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.</description><identifier>ISSN: 0960-7404</identifier><identifier>EISSN: 1879-3320</identifier><identifier>DOI: 10.1016/S0960-7404(10)80020-9</identifier><identifier>PMID: 7582188</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Biomarkers, Tumor - genetics ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - secondary ; Carcinoma, Non-Small-Cell Lung - surgery ; Carcinoma, Squamous Cell - genetics ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - secondary ; Carcinoma, Squamous Cell - surgery ; Disease Progression ; Disease-Free Survival ; Female ; Follow-Up Studies ; Forecasting ; Gene Expression Regulation, Neoplastic ; Genes, p53 - genetics ; Humans ; Incidence ; lung cancer ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Lymph Node Excision ; Lymphatic Metastasis - genetics ; Male ; mediastinal lymph node dissection ; Middle Aged ; Neoplasm Staging ; p53 ; Pneumonectomy ; prognosis ; protein expression ; Survival Rate ; Treatment Outcome</subject><ispartof>Surgical oncology, 1995-06, Vol.4 (3), p.157-161</ispartof><rights>1995 Blackwell Science Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3</citedby><cites>FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7582188$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sauter, E.R.</creatorcontrib><creatorcontrib>Gwin, J.L.</creatorcontrib><creatorcontrib>Mandel, J.</creatorcontrib><creatorcontrib>Keller, S.M.</creatorcontrib><title>p53 and disease progression in patients with non-small cell lung cancer</title><title>Surgical oncology</title><addtitle>Surg Oncol</addtitle><description>Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread (
P = 0.06), and p53 expression correlated significantly (
P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.</description><subject>Biomarkers, Tumor - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Carcinoma, Squamous Cell - genetics</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>Carcinoma, Squamous Cell - surgery</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Forecasting</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genes, p53 - genetics</subject><subject>Humans</subject><subject>Incidence</subject><subject>lung cancer</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Lymph Node Excision</subject><subject>Lymphatic Metastasis - genetics</subject><subject>Male</subject><subject>mediastinal lymph node dissection</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>p53</subject><subject>Pneumonectomy</subject><subject>prognosis</subject><subject>protein expression</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0960-7404</issn><issn>1879-3320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNqFkE9PAyEQxYnR1Fr9CE04GT2sDuwusCdjGq0mTTyoZ0JhWjEtW2Gr8dtL_6RXL0DmvZk3_AgZMrhhwMTtKzQCCllBdcXgWgFwKJoj0mdKNkVZcjgm_YPllJyl9AkAQnLWIz1ZK86U6pPxqi6pCY46n9AkpKvYziOm5NtAfaAr03kMXaI_vvugoQ1FWprFglrMx2Id5tSaYDGek5OZWSS82N8D8v748DZ6KiYv4-fR_aSwpYCuMA4rzk3jKuYUn-LMMYsSp1kUdcWEYNOZaxpW54eTAhnwSkklUSiuSmnLAbnczc17fq0xdXrp02YZE7BdJy2lhKqpymysd0Yb25QizvQq-qWJv5qB3gDUW4B6Q2dT2gLUTe4b7gPW0yW6Q9eeWNbvdjrmX357jDrZTMii8xFtp13r_0n4A3S0fs4</recordid><startdate>19950601</startdate><enddate>19950601</enddate><creator>Sauter, E.R.</creator><creator>Gwin, J.L.</creator><creator>Mandel, J.</creator><creator>Keller, S.M.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950601</creationdate><title>p53 and disease progression in patients with non-small cell lung cancer</title><author>Sauter, E.R. ; Gwin, J.L. ; Mandel, J. ; Keller, S.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Carcinoma, Squamous Cell - genetics</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>Carcinoma, Squamous Cell - surgery</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Forecasting</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genes, p53 - genetics</topic><topic>Humans</topic><topic>Incidence</topic><topic>lung cancer</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Lymph Node Excision</topic><topic>Lymphatic Metastasis - genetics</topic><topic>Male</topic><topic>mediastinal lymph node dissection</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>p53</topic><topic>Pneumonectomy</topic><topic>prognosis</topic><topic>protein expression</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sauter, E.R.</creatorcontrib><creatorcontrib>Gwin, J.L.</creatorcontrib><creatorcontrib>Mandel, J.</creatorcontrib><creatorcontrib>Keller, S.M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sauter, E.R.</au><au>Gwin, J.L.</au><au>Mandel, J.</au><au>Keller, S.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>p53 and disease progression in patients with non-small cell lung cancer</atitle><jtitle>Surgical oncology</jtitle><addtitle>Surg Oncol</addtitle><date>1995-06-01</date><risdate>1995</risdate><volume>4</volume><issue>3</issue><spage>157</spage><epage>161</epage><pages>157-161</pages><issn>0960-7404</issn><eissn>1879-3320</eissn><abstract>Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread (
P = 0.06), and p53 expression correlated significantly (
P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>7582188</pmid><doi>10.1016/S0960-7404(10)80020-9</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0960-7404 |
ispartof | Surgical oncology, 1995-06, Vol.4 (3), p.157-161 |
issn | 0960-7404 1879-3320 |
language | eng |
recordid | cdi_proquest_miscellaneous_77704943 |
source | Elsevier |
subjects | Biomarkers, Tumor - genetics Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - secondary Carcinoma, Non-Small-Cell Lung - surgery Carcinoma, Squamous Cell - genetics Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - secondary Carcinoma, Squamous Cell - surgery Disease Progression Disease-Free Survival Female Follow-Up Studies Forecasting Gene Expression Regulation, Neoplastic Genes, p53 - genetics Humans Incidence lung cancer Lung Neoplasms - genetics Lung Neoplasms - pathology Lung Neoplasms - surgery Lymph Node Excision Lymphatic Metastasis - genetics Male mediastinal lymph node dissection Middle Aged Neoplasm Staging p53 Pneumonectomy prognosis protein expression Survival Rate Treatment Outcome |
title | p53 and disease progression in patients with non-small cell lung cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A26%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=p53%20and%20disease%20progression%20in%20patients%20with%20non-small%20cell%20lung%20cancer&rft.jtitle=Surgical%20oncology&rft.au=Sauter,%20E.R.&rft.date=1995-06-01&rft.volume=4&rft.issue=3&rft.spage=157&rft.epage=161&rft.pages=157-161&rft.issn=0960-7404&rft.eissn=1879-3320&rft_id=info:doi/10.1016/S0960-7404(10)80020-9&rft_dat=%3Cproquest_cross%3E77704943%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77704943&rft_id=info:pmid/7582188&rfr_iscdi=true |